• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by REGENXBIO Inc.

    3/13/25 5:01:04 PM ET
    $RGNX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $RGNX alert in real time by email
    S-8 1 rgnx-s8-2025-03-13.htm S-8 S-8

     

    As filed with the Securities and Exchange Commission on March 13, 2025

     

    Registration No. 333-

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

    REGENXBIO Inc.

    (Exact name of registrant as specified in its charter)

     

     

    Delaware

    47-1851754

    (State or other jurisdiction of

    incorporation or organization)

    (I.R.S. Employer

    Identification No.)

     

     

    9804 Medical Center Drive

    Rockville, Maryland 20850

    (Address of Principal Executive Offices and Zip Code)

     

    2015 Equity Incentive Plan

     

    (Full title of the plans)

    Mitchell Chan

    Chief Financial Officer

    REGENXBIO Inc.

    9804 Medical Center Drive

    Rockville, Maryland 20850

    (Name and address of agent for service)

    (240) 552-8181

    (Telephone number, including area code, of agent for service)

    Copies to:

     

    Kerry Shannon Burke

    Patrick J. Christmas

    Matthew C. Franker

    Chief Legal Officer

    Covington & Burling LLP

    REGENXBIO Inc.

    One CityCenter

    9804 Medical Center Drive

    850 Tenth Street, N.W.

    Rockville, Maryland 20850

    Washington, D.C. 20001

    (240) 552-8181

    (202) 662-6000

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b‑2 of the Exchange Act.

     

    Large accelerated filer

    

    Accelerated filer

    

    Non-accelerated filer

    

    Smaller reporting company

    

     

     

    Emerging growth company

    

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. 

     

     


     

    EXPLANATORY NOTE

    This Registration Statement on Form S-8 (the “Registration Statement”) is filed by REGENXBIO Inc. (the “Company”) for the purpose of registering additional shares of its common stock, par value $0.0001 per share (the “Common Stock”), under the Company’s 2015 Equity Incentive Plan (the “Incentive Plan”).

    The number of shares of Common Stock available for issuance under the Incentive Plan is subject to an automatic annual increase as of the first business day of the Company’s fiscal year equal to the lower of (a) 4.0% of the total number of shares of Common Stock outstanding on December 31 of the prior year or (b) a number of shares of Common Stock determined by the Company’s Board of Directors (the “Incentive Plan Provision”). Accordingly, the number of shares of Common Stock available for issuance under the Incentive Plan was increased by 1,981,975 shares effective January 2, 2025. This Registration Statement registers the offer and sale of the 1,981,975 additional shares of Common Stock that are available for issuance under the Incentive Plan as a result of the Incentive Plan Provision.

    Of the 17,928,064 shares of Common Stock currently authorized by the Incentive Plan, in addition to the shares, the offer and sale of which are being registered hereby, the Company has previously registered the offer and sale of: (a) 2,952,100 shares of Common Stock pursuant to the Company’s Registration Statement on Form S-8 filed on September 17, 2015 (Commission File No. 333-206984), (b) 1,052,538 shares of Common Stock pursuant to the Company’s Registration Statement on Form S-8 filed on March 3, 2016 (Commission File No. 333-209899), (c) 1,059,065 shares of Common Stock pursuant to the Company’s Registration Statement on Form S-8 filed on March 7, 2017 (Commission File No. 333-216508), (d) 1,251,810 shares of Common Stock pursuant to the Company’s Registration Statement on Form S-8 filed on March 6, 2018 (Commission File No. 333-223466), (e) 1,444,808 shares of Common Stock pursuant to the Company’s Registration Statement on Form S-8 filed on February 27, 2019 (Commission File No. 333-229910), (f) 1,479,696 shares of Common Stock pursuant to the Company’s Registration Statement on Form S-8 filed on February 26, 2020 (Commission File No. 333-236664), (g) 1,499,037 shares of Common Stock pursuant to the Company’s Registration Statement on Form S-8 filed on March 1, 2021 (Commission File No. 333-253725), (h) 1,713,246 shares of Common Stock to the Company’s Registration Statement on Form S-8 filed on March 1, 2022 (Commission File No. 333-263182), (i) 1,731,940 shares of Common Stock to the Company’s Registration Statement on Form S-8 filed on February 28, 2023 (Commission File No. 333-270116) and (j) 1,761,849 shares of Common Stock to the Company's Registration Statement on Form S-8 filed on February 27, 2024 (Commission File No. 333-277412) (collectively, the “Original Incentive Plan Registration Statements”).

    Pursuant to General Instruction E to Form S-8 under the Securities Act of 1933, as amended, the contents of the Original Incentive Plan Registration Statements, including any amendments thereto or filings incorporated therein by reference are incorporated herein by reference and made part of this Registration Statement. Any items in the Original Incentive Plan Registration Statements not expressly changed hereby shall be as set forth in the Original Incentive Plan Registration Statements.

     


     

    PART II

    Information Required in the Registration Statement

    Item 3. Incorporation of Documents by Reference.

    The following documents (File No. 001-37553) previously filed with the Securities and Exchange Commission (the “SEC”) are hereby incorporated by reference:

    •
    the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 13, 2025 (the “2024 Annual Report”);
    •
    the information specifically incorporated by reference into the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 from the Company’s definitive proxy statement on Schedule 14A for the 2024 Annual Meeting of Stockholders, filed with the SEC on April 4, 2024;
    •
    all other reports filed with the SEC pursuant to Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), since the end of the fiscal year covered by the Company’s 2024 Annual Report; and
    •
    the description of the Company’s Common Stock contained in Exhibit 4.2 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 13, 2025, including any amendments or reports filed for the purposes of updating this description.

    All reports and other documents subsequently filed by us pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, prior to the filing of a post-effective amendment which indicates that all securities registered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the date of filing of such documents, except as to specific sections of such statements as set forth therein.

    Unless expressly incorporated into this Registration Statement, a report furnished on Form 8-K (or any portion thereof so furnished) prior or subsequent to the date hereof shall not be incorporated by reference into this Registration Statement. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained in any subsequently filed document which also is deemed to be incorporated by reference herein modifies or supersedes such statement.

     


     

    Item 8. Exhibits.

     

    Exhibit No.

    Description

    4.1*

    Restated Certificate of Incorporation (incorporated by reference from Exhibit 3.1 to the Company’s Current Report on Form 8-K, filed with the SEC on June 7, 2021).

    4.2*

    Amended and Restated Bylaws (incorporated by reference from Exhibit 3.2 to the Company’s Current Report on Form 8-K, filed with the SEC on September 22, 2015).

    4.3*

    Specimen stock certificate evidencing the shares of Common Stock (incorporated by reference from Exhibit 4.1 to the Company’s Registration Statement on Form S-1, filed with the SEC on August 17, 2015).

    4.4*

    2015 Equity Incentive Plan (incorporated by reference from Exhibit 10.3 to Amendment No. 2 to the Company’s Registration Statement on Form S-1, filed with the SEC on September 15, 2015).

    4.5*

    Form of Restricted Stock Unit Award Agreement for the 2015 Equity Incentive Plan (incorporated by reference from Exhibit 10.4 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC on March 1, 2021).

    4.6*

    Form of Stock Option Award Agreement for the 2015 Equity Incentive Plan (incorporated by reference from Exhibit 10.5 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC on March 1, 2021).

    5.1

    Opinion and Consent of Covington & Burling LLP.

    23.1

    Consent of PricewaterhouseCoopers LLP, Independent Registered Public Accounting Firm.

    23.2

    Consent of Covington & Burling LLP (contained in Exhibit 5.1).

    24.1

    Power of Attorney (contained on signature page hereto).

    107

    Filing Fee Table.

     

    * Incorporated by reference

     


     

    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Rockville, State of Maryland, on this 13th day of March, 2025.

     

    REGENXBIO INC.

     

     

    By:

    /s/ Curran Simpson

     

    Curran Simpson

     

    President and Chief Executive Officer

     

    POWER OF ATTORNEY AND SIGNATURES

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Kenneth T. Mills and Patrick J. Christmas, and each of them, as his or her true and lawful attorneys-in-fact and agents with full power of substitution and resubstitution, for him or her in any and all capacities, to sign any and all amendments to this Registration Statement on Form S-8 (including post-effective amendments), and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature

    Title

    Date

     

    /s/ Curran Simpson

    Curran Simpson

     

     

    President, Chief Executive Officer and Director

    (Principal Executive Officer)

     

    March 13, 2025

    /s/ Mitchell Chan

    Mitchell Chan

     

    Chief Financial Officer

    (Principal Financial and Accounting Officer)

    March 13, 2025

    /s/ Kenneth T. Mills

    Kenneth T. Mills

     

    Chairman of the Board of Directors

    March 13, 2025

    /s/ Jean Bennett

    Jean Bennett

     

    Director

    March 13, 2025

    /s/ Allan M. Fox

    Director

    March 13, 2025

    Allan M. Fox

     

    /s/ Alexandra Glucksmann

    Alexandra Glucksmann

     

    Director

    March 13, 2025

    /s/ A.N. “Jerry” Karabelas

    A.N. “Jerry” Karabelas

     

    Director

    March 13, 2025

    /s/ George Migausky

    George Migausky

     

    Director

    March 13, 2025

    /s/ David C. Stump

    David C. Stump

     

    Director

    March 13 2025

    /s/ Daniel Tassé

    Daniel Tassé

    Director

    March 13, 2025

    /s/ Jennifer Zachary

    Director

    March 13, 2025

    Jennifer Zachary

     

     

     

     


     

     

     


    Get the next $RGNX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RGNX

    DatePrice TargetRatingAnalyst
    1/28/2026$37.00Overweight
    Barclays
    2/11/2025$38.00 → $14.00Buy → Neutral
    Goldman
    2/7/2025$27.00Outperform
    Raymond James
    11/15/2024$22.00Overweight
    Morgan Stanley
    10/10/2024$18.00Outperform
    Raymond James
    6/7/2024$38.00Buy
    Goldman
    3/11/2024$36.00Buy
    H.C. Wainwright
    3/8/2024$20.00 → $35.00Sector Perform → Outperform
    RBC Capital Mkts
    More analyst ratings

    $RGNX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Strategy & Legal Officer Christmas Patrick J. covered exercise/tax liability with 4,700 shares, decreasing direct ownership by 2% to 210,667 units (SEC Form 4)

    4 - REGENXBIO Inc. (0001590877) (Issuer)

    2/3/26 4:47:01 PM ET
    $RGNX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Medical Officer Pakola Steve covered exercise/tax liability with 5,267 shares, decreasing direct ownership by 2% to 253,050 units (SEC Form 4)

    4 - REGENXBIO Inc. (0001590877) (Issuer)

    2/3/26 4:46:40 PM ET
    $RGNX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Mills Kenneth T. exercised 225,000 shares at a strike of $13.09 and covered exercise/tax liability with 221,753 shares, increasing direct ownership by 0.67% to 486,118 units (SEC Form 4)

    4 - REGENXBIO Inc. (0001590877) (Issuer)

    1/29/26 4:58:46 PM ET
    $RGNX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $RGNX
    SEC Filings

    View All

    REGENXBIO Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - REGENXBIO Inc. (0001590877) (Filer)

    1/28/26 8:30:24 AM ET
    $RGNX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by REGENXBIO Inc.

    SCHEDULE 13G/A - REGENXBIO Inc. (0001590877) (Subject)

    1/21/26 12:26:45 PM ET
    $RGNX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form EFFECT filed by REGENXBIO Inc.

    EFFECT - REGENXBIO Inc. (0001590877) (Filer)

    12/15/25 12:15:33 AM ET
    $RGNX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $RGNX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays resumed coverage on REGENXBIO with a new price target

    Barclays resumed coverage of REGENXBIO with a rating of Overweight and set a new price target of $37.00

    1/28/26 7:18:39 AM ET
    $RGNX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    REGENXBIO downgraded by Goldman with a new price target

    Goldman downgraded REGENXBIO from Buy to Neutral and set a new price target of $14.00 from $38.00 previously

    2/11/25 7:12:20 AM ET
    $RGNX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Raymond James resumed coverage on REGENXBIO with a new price target

    Raymond James resumed coverage of REGENXBIO with a rating of Outperform and set a new price target of $27.00

    2/7/25 8:29:59 AM ET
    $RGNX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $RGNX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    REGENXBIO Announces Regulatory Update on RGX-121 BLA for MPS II

    FDA issues Complete Response Letter for RGX-121 (clemidsogene lanparvovec) for treatment of Mucopolysaccharidosis II (MPS II) REGENXBIO plans to work with FDA on a path forward with the goal of resubmitting the BLAROCKVILLE, Md., Feb. 9, 2026 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding its Biologics License Application (BLA) for RGX-121 (clemidsogene lanparvovec) for the treatment of Mucopolysaccharidosis II (MPS II), an ultra-rare neurodegenerative disease also known as Hunter syndrome. In May 2025, the FDA accepted the RGX-121 BLA under the accelerated approval pathway. I

    2/9/26 4:05:00 PM ET
    $RGNX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    REGENXBIO Announces Regulatory Update on Ultra Rare MPS Programs

    ROCKVILLE, Md., Jan. 28, 2026 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today announced that the U.S. Food and Drug Administration (FDA) placed a clinical hold on its investigational gene therapy, RGX-111, for the treatment of MPS I, also known as Hurler syndrome, following preliminary analysis of a single case of neoplasm (intraventricular CNS tumor) in a participant treated in its Phase I/II study. The FDA also placed a clinical hold on RGX-121, for the treatment of MPS II, also known as Hunter Syndrome, citing the similarities in products, study populations, and shared risk between the clinical studies. The case was identified during a routine brain MRI of an asymptomatic five-year-old

    1/28/26 7:30:00 AM ET
    $RGNX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    REGENXBIO Highlights Key 2026 Catalysts and Announces Positive Long-Term Functional Outcomes in Lead Duchenne Gene Therapy Program

    New Phase I/II RGX-202 functional data demonstrates long-term, durable treatment effect at pivotal dose at 18 months  Robust patient enrollment in confirmatory trial continues, expect majority of patients to be dosed by planned BLA filing, mid-yearExpecting FDA PDUFA decision and multiple pivotal top-line data readouts in 2026 to support potential commercial launches 2026-2028 In-house manufacturing and strategic global partnerships driving commercial readinessPresentation at 44th Annual J.P. Morgan Healthcare Conference Wednesday, January 14ROCKVILLE, Md., Jan. 11, 2026 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) highlighted progress and upcoming anticipated milestones across its pipeline

    1/11/26 3:00:00 PM ET
    $RGNX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $RGNX
    Financials

    Live finance-specific insights

    View All

    REGENXBIO Reports Third Quarter 2025 Financial Results and Operational Highlights

    RGX-202 program for Duchenne muscular dystrophy advancing rapidly, topline results expected early Q2 2026 and BLA submission mid-2026Pivotal trial enrollment completed in October; confirmatory trial open and enrolling New 12-month analysis shows all participants demonstrate improved functional outcomes across multiple natural history methods of measurement, when decline is expectedClemidsogene lanparvovec (RGX-121) on track to be first gene therapy and one-time treatment for MPS II; PDUFA date February 8, 2026Surabgene lomparvovec (sura-vec, ABBV-RGX-314) on track to be first gene therapy for chronic retinal diseaseEnrollment completed in pivotal trials evaluating subretinal delivery of sura

    11/6/25 7:05:00 AM ET
    $RGNX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    REGENXBIO to Host Conference Call on November 6 to Discuss Third Quarter 2025 Financial Results and Operational Highlights

    ROCKVILLE, Md., Oct. 29, 2025 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today announced that it will host a conference call on Thursday, November 6, at 8:00 a.m. ET to discuss its financial results for the third quarter ended September 30, 2025, and operational highlights. Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the company's investor website approximately two hours after the call's conclusion. Those who plan on participating are advised to join 15 minutes prior to the start time. ABOUT REGENXBIO Inc. REGENXBIO is a biotechnology company on a

    10/29/25 7:05:00 AM ET
    $RGNX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    REGENXBIO Reports Second Quarter 2025 Financial Results and Operational Highlights

    RGX-202 in Duchenne muscular dystrophy on track for topline results 1H 2026 and BLA submission mid-2026Pivotal trial enrollment accelerated, expected to complete in October 2025 ahead of previous guidanceClemidsogene lanparvovec (RGX-121) on track to be first gene therapy and one-time treatment for MPS II; FDA inspections completed successfullyPre-license inspection (PLI) of in-house manufacturing facility, quality systems and processes completed with no observationsBioresearch monitoring information (BIMO) inspection of laboratory and clinical data practices completed with no observationsSurabgene lomparvovec (sura-vec, ABBV-RGX-314) on track to be first gene therapy in chronic retinal dise

    8/7/25 7:05:00 AM ET
    $RGNX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $RGNX
    Leadership Updates

    Live Leadership Updates

    View All

    Apollo Global Management and Workday Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

    NEW YORK, Dec. 6, 2024 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, December 23, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from t

    12/6/24 6:29:00 PM ET
    $AMTM
    $APO
    $CMA
    Real Estate
    Investment Managers
    Finance
    Major Banks

    REGENXBIO Appoints Mitchell Chan as Chief Financial Officer

    Life sciences veteran Mitchell Chan joins the company ahead of multiple catalysts across late-stage gene therapy programsVit Vasista steps down following more than 15 years at the CompanyROCKVILLE, Md., Sept. 17, 2024 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today announced that Mitchell Chan has been appointed as Executive Vice President and Chief Financial Officer, effective today. A veteran finance executive and operating partner in the biotechnology industry, Mr. Chan has held key roles in raising capital, business development transactions and operations for nearly 20 years.  "We are excited to welcome Mitchell at this exciting time for REGENXBIO," said Curran Simpson, President and

    9/17/24 7:05:00 AM ET
    $RGNX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    REGENXBIO Announces Leadership Transition

    Curran Simpson, Chief Operating Officer, Appointed as President and CEOCo-Founder Kenneth T. Mills to Step Down as President and CEO; Named Chairman of the Board ROCKVILLE, Md., June 12, 2024 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today announced that Curran Simpson, Chief Operating Officer, has been appointed as President, Chief Executive Officer and a member of the Board of Directors, effective July 1, 2024. Co-Founder Kenneth T. Mills will step down as President and Chief Executive Officer following 15 years of leadership at the Company, and he is taking on an expanded role on the Board as Chairman. In connection with these changes, Board member Daniel Tassé has been appointed as RE

    6/12/24 7:05:00 AM ET
    $RGNX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $RGNX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by REGENXBIO Inc.

    SC 13G/A - REGENXBIO Inc. (0001590877) (Subject)

    11/14/24 9:00:57 PM ET
    $RGNX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by REGENXBIO Inc.

    SC 13G/A - REGENXBIO Inc. (0001590877) (Subject)

    11/12/24 4:47:45 PM ET
    $RGNX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by REGENXBIO Inc.

    SC 13G/A - REGENXBIO Inc. (0001590877) (Subject)

    11/4/24 1:49:56 PM ET
    $RGNX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care